AIM
EVFM

Acrospire Investment Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Acrospire Investment Management’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-23
Closed -$1K – 1672
2017
Q2 		$1K Buy
+23
New +$4.03K ﹤0.01% 2117
2016
Q3 		– Sell
-14
Closed -$1K – 2234
2016
Q2 		$1K Buy
+14
New +$1.25K ﹤0.01% 1977

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CCG
Ceeto Capital Group Coral Gables, Florida $326M AUM 24.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WAS
WESPAC Advisors SoCal Pasadena, California $560M AUM 37.11% 1-Year Est. Return

Acrospire Investment Management's EVFM Position: Q3 2017 in Review

Acrospire Investment Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2017, closing a stake of 23 shares — an estimated $1K sold.

Acrospire Investment Management first reported a position in EVFM in Q2 2016 and held it in 2 quarters. The position peaked at $1K in Q2 2017. 11 funds tracked by Wall St. Rank hold EVFM as of Q3 2017.

  • Acrospire Investment Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 23 Evofem Biosciences, Inc. Common Stock shares in Q3 2017, an estimated $1K.
  • Acrospire Investment Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Evofem Biosciences, Inc. Common Stock position peaked at $1K in Q2 2017.
  • 11 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.